Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial. Findings from the phase 3 AGILE trial showed ...

Vidaza has been designated as an Orphan Medicinal Product in the EU for the treatment of MDS, which, if approved, entitles the drug to ten years of market exclusivity for the approved indication.

Vidaza boasts a long-established place in conventional treatment for patients with acute myeloid leukemia (AML). Now, its active ingredient, azacitidine, has been spun into an oral option. The FDA ...

Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...

Two year survival rate of 50.8 percent for Vidaza versus 26.2 for conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to conventional care regimens Only agent ...

The cost regulator for National Health Service therapies in England and Wales has closed the door to Celgene’s Vidaza as a treatment for a group of blood disorders on grounds that it is too expensive.

Celgene announced results from a Phase 2 study evaluating the combination of Revlimid (lenalidomide) plus Vidaza (azacitidine) in patients ≥60 years with untreated acute myeloid leukemia (AML).

If a recent survey of 100 hematologists and oncologists is any indicator, then Vidaza (azacitidine), Pharmion Corp.'s pyrimidine nucleoside analogue approved in May, could be poised to snag a major ...

Data from the global, multi-center, randomized, open-label study revealed a median overall survival (the primary endpoint) of 10.4 months for patients treated with Vidaza as against 6.5 months for ...

BOSTON, Dec. 9 (Reuters) - Pharmion Corp said on Sunday that detailed analysis of a late-stage clinical trial of its drug to treat a group of blood disorders known as myelodysplastic syndromes ...

Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgene’s Vidaza for the National ...